SLC19A1 Polymorphism and Serum Methotrexate in Patients with Acute Lymphoblastic Leukemia

Beuy Joob; Viroj Wiwanitkit

doi:10.4103/ijmpo.ijmpo_6_16

Indian Journal of Medical and Paediatric Oncology, Table of Contents

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2018; 39(01): 120-121
DOI: 10.4103/ijmpo.ijmpo_6_16

Short Communication

SLC19A1 Polymorphism and Serum Methotrexate in Patients with Acute Lymphoblastic Leukemia

Beuy Joob

Sanitation 1 Medical Academic Center, Bangkok, Thailand

,

Viroj Wiwanitkit

Department of Tropical Medicine, Hainan Medical University, Haikou, China; Department of Medicine, Faculty of Medicine, University of Nis, Nis, Serbia; Department of Biological Science, Joseph Ayobabalola University, Ilara-Mokin, Nigeria; Department of Community Medicine, Dr. DY Patil Medical University, Pune, Maharashtra, India

› Author Affiliations

Abstract

Acute lymphoblastic leukemia (ALL) is a common pediatric malignancy. Methotrexate is the widely used chemotherapy for ALL. The polymorphism (rs1051296) of SLC19A1 is proposed for its effect on serum methotrexate. To explain this observation, the authors hereby studied the interrelationship between SLC19A1 polymorphism and blood methotrexate level in the patients with ALL. Here, the authors use a quantum chemistry analysis for explaining of this observation.

Keywords

Acute lymphoblastic leukemia - methotrexate - polymorphism

Full Text

References

References
1 Pui CH, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A. et al. Childhood acute lymphoblastic leukemia: Progress through collaboration. J Clin Oncol 2015; 33: 2938-48
2 Koh K. Current treatment of pediatric acute lymphoblastic leukemia. Rinsho Ketsueki 2014; 55: 2225-32
3 Tasian SK, Loh ML, Hunger SP. Childhood acute lymphoblastic leukemia: Integrating genomics into therapy. Cancer 2015; 121: 3577-90
4 Wang SM, Sun LL, Zeng WX, Wu WS, Zhang GL. Effects of a microRNA binding site polymorphism in SLC19A1 on methotrexate concentrations in Chinese children with acute lymphoblastic leukemia. Med Oncol 2014; 31: 62
5 Wiwanitkit V. Analysis of binding energy activity of imatinib and Abl tyrosine kinase domain based on simple consideration for conformational change: An explanation for variation in imatinib effect in mutated type. Indian J Cancer 2009; 46: 335-6
6 Dulucq S, Laverdière C, Sinnett D, Krajinovic M. Pharmacogenetic considerations for acute lymphoblastic leukemia therapies. Expert Opin Drug Metab Toxicol 2014; 10: 699-719
7 Gutierrez-Camino A, Lopez-Lopez E, Garcia-Orad A. SLC19A1 hot spot for MTX plasma concentration. Med Oncol 2014; 31: 204